European Patent Office

T 0990/96 (Erythro-compounds/NOVARTIS) vom 12.02.1998

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:1998:T099096.19980212
Datum der Entscheidung
12. Februar 1998
Aktenzeichen
T 0990/96
Antrag auf Überprüfung von
-
Anmeldenummer
93106005.7
IPC-Klasse
C07C 69/732
Verfahrenssprache
Englisch
Verteilung
Im Amtsblatt des EPA veröffentlicht (A)
Amtsblattfassungen
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Acides hept-6-énoiques et heptanoiques substitués sur la position 7 et dérivés de ceux-ci
Name des Antragstellers
Novartis AG
Name des Einsprechenden
Novartis AG
Kammer
3.3.01
Leitsatz

1. It is common practice for a person skilled in the art of preparative organic chemistry to (further) purify a compound obtained in a particular chemical manufacturing process according to the prevailing needs and requirements. Since, as a rule, conventional methods for the purification of low molecular organic compounds are within his common general knowledge, a document disclosing a low molecular chemical compound and its manufacture makes normally available this compound to the public in the sense of Article 54 EPC in all desired grades of purity (no. 7 of the reasons for the decision).

2. If a party alleges that this general rule would not be applicable in a particular case, then the burden of proving the existence of such an exceptional situation, e.g. of a situation where all prior attempts to achieve a particular degree of purity by conventional purification processes have failed, lies with the party who alleges such a situation (no. 8 of the reasons for the decision).

Schlagwörter
Novelty (no)
Purity of chemical compound no new element
Orientierungssatz
-

ORDER

For these reasons it is decided that:

The appeal is dismissed.